查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1209802

全球人用胰岛素市场：到 2028 年的预测 - 按产品类型、糖尿病类型、分销渠道和地区分析

Human Insulin Market Forecasts to 2028 - Global Analysis By Product Type, Diabetes Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球人胰岛素市场预计在 2022 年将达到 187 亿美元，到 2028 年将达到 248 亿美元，预测期内的复合年增长率为 4.7%。 .

人胰岛素 (HI) 是一种短效胰岛素，用于治疗 1 型和 2 型糖尿病引起的高血糖症。 人胰岛素是通过基因重组技术生产的，与内源□□性胰岛素相同。 通常用作身体製造的胰岛素的替代品，它有助于将血液中的糖分结合到其他身体组织并将其用于能量。 胰岛素是由胰腺的β细胞产生的一种激素。 在调节葡萄糖水平方面起重要作用。 它调节体内的系统并调节身体细胞对氨基酸的吸收。

根据美国疾病控制和预防中心的数据，20 岁以上的人中约有 160 万人患有 1 型糖尿病并使用胰岛素。 根据亚洲糖尿病预防倡议，由于生活方式和饮食趋势，亚洲人患糖尿病的风险更高。

市场动态

驱动程序

糖尿病患病率增加

生活方式和饮食的改变显着增加了患有肥胖症和糖尿病的人口比例。 此外，胰岛素製造技术发展显着，渗透率不断提高。 胰岛素製造技术进步显着，普及率越来越高。 结果，胰岛素变得更便宜，更容易获得。

抑製剂

成本高

糖尿病患者一生需要频繁服用胰岛素製剂，因此经济负担沉重。 由于需要高技能人员和復杂的製造基础设施，製造成本很高。 胰岛素类似物的高成本是製约人胰岛素市场增长的主要因素。 此外，胰岛素审批的严格监管要求也是潜在的製约因素。

机会

增加研发活动的投资

多个组织不断增加对研发活动的投资，创造了先进而简单的胰岛素注射方法，促进了市场的增长。 此外，更安全的笔型设备和笔型注射针头用于有效注射胰岛素的引入以及糖尿病意识的提高预计将推动需求。 行业领先公司在生物技术领域的医疗保健基础设施的显着改善和广泛的研发活动正在推动市场增长。

威胁

严格的规定

药品审批受到严格的监管。 医疗器械法规需要完善，以确保用户能够获得优质、有效和安全的技术。 医疗器械的激增和现代化带来了新的监管挑战。 供需关係也开始受到药物批准所需时间的不利影响。 这些因素将製约人胰岛素市场。

COVID-19 的影响

COVID-19 对人胰岛素市场产生了反射性影响。 对旅行和货物流动的限制已对供应链造成重大破坏。 此外，为遏制病毒传播而暂时关闭製造设备也降低了生产率。 结果，全球人胰岛素供应出现了短暂但严重的短缺。 此外，健康检查因疫情停业而延期，导致检测量和试剂销量下降。 不过，随着世界各国政府的旅行限制逐渐放宽，检查数量正在恢復。

胰岛素类似物和生物仿製药有望在预测期内成为最大的

与传统治疗相比，胰岛素类似物和生物仿製药部分由于胰岛素效率更高，副作用更少，例如低血糖事件减少和体重增加，预计将实现有利可图的增长。 坚持治疗和血糖控制也很高。 此外，这些产品的销售和处方率预计在未来几年内会下降，因为与传统产品相比，更有效的胰岛素类似物的低血糖风险更低。

预计零售和在线药店在预测期内的复合年增长率最高。

由于疾病负担的增加、家庭护理患者的可行性以及零售药店提供的各种折扣，预计零售和在线药店部分在预测期内将呈现最快的复合年增长率。 网上药品购买的舒适性、灵活性和便利性是推动这一细分市场的主要因素。 此外，由于在线药店提供的折扣以及糖尿病患者住院率的增加，患者在线购买药品的增加也有望推动市场增长。

市场份额最高的地区

由于人口老龄化、生物仿製药开发研究合作的增加、大公司的地域扩张以及政府和非营利组织进入市场等因素，亚太地区在预测期内将继续增长。它是预计将占据最大的市场份额。 此外，针对这种疾病的健康意识运动和科学会议可能会推动该地区的市场增长。

复合年增长率最高的地区

由于人口老龄化、糖尿病患病率上升、医疗保健意识提高、报销政策改善以及临床试验激增等因素，北美将在预测期内实现最高复合年增长率。预测。 此外，主要胰岛素製造商的存在、公司之间的激烈竞争以及 1 型糖尿病患病率上升正在推动该地区的增长。

主要发展

2021 年 11 月，Novo Nordisk A/s 收购了 Dicerna Pharmaceuticals，其中包括 Novo Nordisk 用于所有治疗领域的研究技术平台，以及 Dicerna 的核糖核酸干扰 (RNAi) 平台。

2021 年 2 月，Biocon Biologics 与国际糖尿病联合会 (IDF) 合作，成为第一家推动和支持 IDF 重要使命的胰岛素生物仿製药公司。 该合作伙伴关係标誌着胰岛素发明 100 週年的开始，并推进了 Biocon Biologics 为全球糖尿病患者提供负担得起的胰岛素的目标。

本报告的内容

  • 区域和国家细分市场份额评估
  • 针对新进入者的战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 涵盖市场趋势（市场驱动因素、驱动因素、机遇、威胁、挑战、投资机会、建议）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局映射主要共同趋势
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 映射最新技术进步的供应链趋势

免费定制服务

订阅此报告的客户将免费获得以下自定义选项之一。

  • 公司简介
    • 其他市场参与者的综合概况（最多 3 家公司）
    • 主要参与者的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 根据客户要求对主要国家/地区的市场进行估算、预测和復合年增长率（注意：基于可行性检查。）
  • 竞争基准
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究信息来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球人胰岛素市场：产品类型

  • 常规人胰岛素
    • 短效生物製剂
    • 中效生物製剂
    • 混合生物製品
  • 胰岛素类似物和生物仿製药
    • 速效生物仿製药
    • 长效生物类似药
    • 预混生物仿製药
  • 其他产品类型

第 6 章全球人胰岛素市场：按糖尿病类型分类

  • I 型糖尿病
  • II 型糖尿病
  • 其他类型的糖尿病

第 7 章全球人胰岛素市场：按分销渠道

  • 零售店和在线药店
  • 医院药房
  • 其他分销渠道

第 8 章全球人胰岛素市场：区域

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东地区

第九章主要进展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章公司简介

  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Tonghua Dongbao Pharmaceutical Co. Ltd.
  • Julphar
  • Biocon Ltd
  • Sanofi
  • United Laboratories International Holdings Limited
  • Pfizer, Inc.
  • Boehringer Ingelheim International GmbH
  • Wockhardt
  • Bristol-Myers Squibb Company.
  • Oramed Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc.
  • Gan & Lee Pharmaceuticals Co Ltd.
  • Ypsomed AG
  • Shanghai Fosun Pharmaceutical Co., Ltd
Product Code: SMRC22224

According to Stratistics MRC, the Global Human Insulin Market is accounted for $18.7 billion in 2022 and is expected to reach $24.8 billion by 2028 growing at a CAGR of 4.7% during the forecast period. Human insulin (HI) is a short-acting form of insulin used to treat hyperglycemia caused by type-1 and type-2 diabetes. It is produced by recombinant DNA technology and identical to endogenously made insulin. It is used to take the place of insulin generally produced by the body and aids in insulating sugar from the blood into other body tissues, wherein it is utilized for energy. Insulin is a hormone made by the beta cells of the pancreas. It plays a vital role in the regulation of glucose levels. It controls the body's systems and regulates the uptake of amino acids by body cells.

According to the Centers for Disease Control and Prevention, around 1.6 million adults aged 20 years or older have Type 1 diabetes and use insulin. According to the Asian Diabetes Prevention Initiative, people in Asia are at a high risk of developing diabetes due to lifestyle and diet trends.

Market Dynamics:

Driver:

Growing Diabetes Prevalence

The proportion of the population suffering from obesity and diabetes has increased significantly due to change in lifestyle and dietary habits. There has been a remarkable development in insulin production technology which is escalating its adoption rate. Newer technologies like recombinant DNA technology have enabled mass production of insulin to meet the huge demand. Consequently, this has made insulin reasonable and available to reach a wider population.

Restraint:

High cost

The patients suffering from diabetes need to take insulin supplements frequently, forever for their lifetime this puts a financial burden on the individuals. The need for highly skilled manpower and complicated manufacturing infrastructure increases the manufacturing cost. The high cost of insulin analogs is the major factor hindering the human insulin market growth. Furthermore, strict regulatory requirements for insulin approval are also a potential restraining factor.

Opportunity:

Rising Investments in R&D Activities

The rising investments in research and development activities by several organisations have led to an advanced and easier way of injecting insulin, which is boosting the market growth. In addition, the introduction of the safety pen devices and pen needles for effective delivery of insulin, growing awareness of diabetes is expected to bolster the demand. The significant improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of biotechnology conducted by leading industry players are strengthening the growth of the market.

Threat:

Strict regulations

There are severe regulations in place for drug approvals. Medical device regulations must be improved so that users can achieve high-quality, effective, and safe technology. The growing number and modernization of medical devices have led to new regulatory challenges. The demand-supply ratio is also getting adversely affected due to the time taken for approval of drugs. These factors are bound to restrain the human insulin market.

COVID-19 Impact

COVID-19 had a reflective impact on the human insulin market. Due to restrictions in travel and movement of goods, there were wide disruptions in the supply chain. Moreover, the temporary shutdown of manufacturing units to curb the virus spread decreased the production rate. Thus, there was a huge shortage of human insulin worldwide for a short period. Lockdowns arising from the epidemic forced people to put off getting their health checked, reducing the amount of tests performed and reagent sales. However, as governments gradually loosen travel restrictions, there is a rebound in testing numbers.

The insulin analogs and biosimilars segment is expected to be the largest during the forecast period

The insulin analogs and biosimilars segment is estimated to have a lucrative growth, due to the higher efficiency of insulin and minimal adverse effects, such as hypoglycemia attacks and lower weight gain, as compared to conventional therapy. It has better observance to therapy and glycemic control. In addition, it does not pose as much a risk of hypoglycemia compared to traditional products, owing to the presence of more effective insulin analogs, the sales and prescription rate of these products are expected to refuse over the forthcoming years.

The retail & online pharmacies segment is expected to have the highest CAGR during the forecast period

The retail & online pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the rising burden of disease, the feasibility of home care patients, and various discounts offered by retail pharmacies. The comfort, flexibility, and convenience provided by online purchase of medications are major factors driving the segment. In addition, the discounts offered by online pharmacies attract patients to purchase medications online, the rising hospitalization of diabetic patients are also expected to fuel market growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to due to factors such as rising geriatric & target populations, increasing number of collaborations for the development of biosimilars, geographic expansion of key players, and active participation of government and non-profit organizations in the market space. Additionally, health awareness campaigns and scientific conferences for the management of this disease may fuel market growth in the region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the factors like growing old age population, rising prevalence of diabetes, increasing healthcare awareness, improvement in reimbursement policies, and surge in clinical trials. The robust presence of the major insulin manufacturers, strong competition among the companies and increasing prevalence of type-1 diabetes are some aspects enhancing the region growth.

Key players in the market

Some of the key players profiled in the Human Insulin Market include Eli Lilly and Company, Novo Nordisk A/S, Tonghua Dongbao Pharmaceutical Co. Ltd., Julphar, Biocon Ltd, Sanofi, United Laboratories International Holdings Limited, Pfizer, Inc., Boehringer Ingelheim International GmbH, Wockhardt, Bristol-Myers Squibb Company., Oramed Pharmaceuticals, Inc., GlaxoSmithKline Plc., Gan & Lee Pharmaceuticals Co Ltd., Ypsomed AG and Shanghai Fosun Pharmaceutical Co., Ltd.

Key Developments:

In November 2021, Novo Nordisk A/s acquired Dicerna Pharmaceuticals, including its Dicerna's ribonucleic acid interference (RNAi) platform, in addition to Novo Nordisk's research technology platforms used across all therapeutic areas.

In February 2021, Biocon Biologics partnered with the International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF's important mission initiative. The collaboration marks the start of the centennial commemoration of the invention of insulin and advances Biocon Biologics' aim of providing inexpensive insulin to individuals with diabetes around the world.

Product Types Covered:

  • Traditional Human Insulin
  • Insulin Analogs and Biosimilars
  • Others Product Types

Diabetes Types Covered:

  • Type I Diabetes
  • Type II Diabetes
  • Other Diabetes Types

Distribution Channels Covered:

  • Retail & Online Pharmacies
  • Hospitals Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Insulin Market, By Product Type

  • 5.1 Introduction
  • 5.2 Traditional Human Insulin
    • 5.2.1 Short-Acting Biologics
    • 5.2.2 Intermediate-Acting Biologics
    • 5.2.3 Premixed Biologics
  • 5.3 Insulin Analogs and Biosimilars
    • 5.3.1 Rapid-Acting Biosimilars
    • 5.3.2 Long-Acting Biosimilars
    • 5.3.3 Premix Biosimilars
  • 5.4 Other Product Types

6 Global Human Insulin Market, By Diabetes Type

  • 6.1 Introduction
  • 6.2 Type I Diabetes
  • 6.3 Type II Diabetes
  • 6.4 Other Diabetes Types

7 Global Human Insulin Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail & Online Pharmacies
  • 7.3 Hospitals Pharmacies
  • 7.4 Other Distribution Channels

8 Global Human Insulin Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Eli Lilly and Company
  • 10.2 Novo Nordisk A/S
  • 10.3 Tonghua Dongbao Pharmaceutical Co. Ltd.
  • 10.4 Julphar
  • 10.5 Biocon Ltd
  • 10.6 Sanofi
  • 10.7 United Laboratories International Holdings Limited
  • 10.8 Pfizer, Inc.
  • 10.9 Boehringer Ingelheim International GmbH
  • 10.10 Wockhardt
  • 10.11 Bristol-Myers Squibb Company.
  • 10.12 Oramed Pharmaceuticals, Inc.
  • 10.13 GlaxoSmithKline Plc.
  • 10.14 Gan & Lee Pharmaceuticals Co Ltd.
  • 10.15 Ypsomed AG
  • 10.16 Shanghai Fosun Pharmaceutical Co., Ltd

List of Tables

  • Table 1 Global Human Insulin Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 3 Global Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 4 Global Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 5 Global Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 6 Global Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 7 Global Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 8 Global Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 9 Global Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 10 Global Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 11 Global Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 12 Global Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 13 Global Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 14 Global Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 15 Global Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 16 Global Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 17 Global Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 18 Global Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 19 Global Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 20 North America Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 21 North America Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 22 North America Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 23 North America Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 24 North America Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 25 North America Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 26 North America Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 27 North America Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 28 North America Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 29 North America Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 30 North America Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 31 North America Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 32 North America Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 33 North America Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 34 North America Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 35 North America Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 36 North America Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 37 North America Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 38 North America Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 39 Europe Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 40 Europe Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 41 Europe Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 42 Europe Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 43 Europe Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 44 Europe Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 45 Europe Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 46 Europe Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 47 Europe Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 48 Europe Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 49 Europe Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 50 Europe Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 51 Europe Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 52 Europe Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 53 Europe Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 54 Europe Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 55 Europe Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 56 Europe Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 57 Europe Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 58 Asia Pacific Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 59 Asia Pacific Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 60 Asia Pacific Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 61 Asia Pacific Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 62 Asia Pacific Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 63 Asia Pacific Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 64 Asia Pacific Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 65 Asia Pacific Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 66 Asia Pacific Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 67 Asia Pacific Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 68 Asia Pacific Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 69 Asia Pacific Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 70 Asia Pacific Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 71 Asia Pacific Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 72 Asia Pacific Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 73 Asia Pacific Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 74 Asia Pacific Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 75 Asia Pacific Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 76 Asia Pacific Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 77 South America Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 78 South America Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 79 South America Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 80 South America Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 81 South America Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 82 South America Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 83 South America Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 84 South America Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 85 South America Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 86 South America Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 87 South America Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 88 South America Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 89 South America Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 90 South America Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 91 South America Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 92 South America Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 93 South America Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 94 South America Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 95 South America Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 96 Middle East & Africa Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 97 Middle East & Africa Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 98 Middle East & Africa Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 99 Middle East & Africa Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 100 Middle East & Africa Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 101 Middle East & Africa Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 102 Middle East & Africa Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 103 Middle East & Africa Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 104 Middle East & Africa Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 105 Middle East & Africa Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 106 Middle East & Africa Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 107 Middle East & Africa Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 108 Middle East & Africa Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 109 Middle East & Africa Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 110 Middle East & Africa Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 111 Middle East & Africa Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 112 Middle East & Africa Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 113 Middle East & Africa Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 114 Middle East & Africa Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)